Haisco Pharmaceutical Group Co., Ltd.

SZSE:002653 Lagerbericht

Marktkapitalisierung: CN¥40.5b

Haisco Pharmaceutical Group Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Haisco Pharmaceutical Group is forecast to grow earnings and revenue by 33.9% and 23% per annum respectively. EPS is expected to grow by 33.6% per annum. Return on equity is forecast to be 15.8% in 3 years.

Wichtige Informationen

33.9%

Wachstumsrate der Gewinne

33.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum19.3%
Wachstumsrate der Einnahmen23.0%
Zukünftige Eigenkapitalrendite15.8%
Analystenabdeckung

Low

Zuletzt aktualisiert03 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

Aug 22
Haisco Pharmaceutical Group's (SZSE:002653) Promising Earnings May Rest On Soft Foundations

With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Jul 25
With Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) It Looks Like You'll Get What You Pay For

Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Jul 04
Haisco Pharmaceutical Group (SZSE:002653) Has A Pretty Healthy Balance Sheet

Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Jun 17
Calculating The Fair Value Of Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well

Mar 19
These 4 Measures Indicate That Haisco Pharmaceutical Group (SZSE:002653) Is Using Debt Reasonably Well

Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Feb 27
Risks To Shareholder Returns Are Elevated At These Prices For Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653)

Gewinn- und Umsatzwachstumsprognosen

SZSE:002653 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (CNY Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
12/31/20266,1599937559243
12/31/20254,9776153215494
12/31/20243,9004861015421
9/30/20243,72247697513N/A
6/30/20243,672385143505N/A
3/31/20243,48435864447N/A
12/31/20233,35529559450N/A
9/30/20233,302375-171299N/A
6/30/20233,138282-447204N/A
3/31/20233,077280-441239N/A
1/1/20233,015277-60695N/A
9/30/20222,959173-57472N/A
6/30/20222,74495-61717N/A
3/31/20222,60784-715-39N/A
1/1/20222,773345-66736N/A
9/30/20212,866509-6951N/A
6/30/20213,154728-342290N/A
3/31/20213,469796-352289N/A
12/31/20203,330637-396206N/A
9/30/20203,326513-266515N/A
6/30/20203,520488-282499N/A
3/31/20203,68757221668N/A
12/31/20193,937494182764N/A
9/30/20194,32941316486N/A
6/30/20194,10542332365N/A
3/31/20193,788323107454N/A
12/31/20183,427333121473N/A
9/30/20182,624337272613N/A
6/30/20182,208247N/A571N/A
3/31/20182,061254N/A438N/A
12/31/20171,856238N/A392N/A
9/30/20171,806335N/A349N/A
6/30/20171,606341N/A313N/A
3/31/20171,535444N/A451N/A
12/31/20161,436443N/A409N/A
9/30/20161,342406N/A395N/A
6/30/20161,326395N/A474N/A
3/31/20161,147315N/A376N/A
12/31/20151,212372N/A443N/A
9/30/20151,179372N/A454N/A
6/30/20151,233434N/A455N/A
3/31/20151,226469N/A459N/A
1/1/20151,211451N/A503N/A
9/30/20141,110520N/A492N/A
6/30/20141,067524N/A522N/A
3/31/20141,031520N/A557N/A
12/31/2013992519N/A568N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 002653's forecast earnings growth (33.9% per year) is above the savings rate (2.9%).

Ertrag vs. Markt: 002653's earnings (33.9% per year) are forecast to grow faster than the CN market (25.8% per year).

Hohe Wachstumserträge: 002653's earnings are expected to grow significantly over the next 3 years.

Einnahmen vs. Markt: 002653's revenue (23% per year) is forecast to grow faster than the CN market (14% per year).

Hohe Wachstumseinnahmen: 002653's revenue (23% per year) is forecast to grow faster than 20% per year.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 002653's Return on Equity is forecast to be low in 3 years time (15.8%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y